Similar articles

• HIV resistance to reverse transcriptase inhibitors.

  De Clercq E. De Clercq E. Biochem Pharmacol. 1994 Jan 20;47(2):155-69. doi: 10.1016/0006-2952(94)90001-9. Biochem Pharmacol. 1994. PMID: 7508227 Review. No abstract available.
• Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.

  Debyser Z, Vandamme AM, Pauwels R, Baba M, Desmyter J, De Clercq E. Debyser Z, et al. J Biol Chem. 1992 Jun 15;267(17):11769-76. J Biol Chem. 1992. PMID: 1376311
• [Inhibitors of HIV-1 reverse transcriptase and protease as chemotherapeutics for AIDS].

  Mitsuya H. Mitsuya H. Nihon Rinsho. 1991 Sep;49(9):2062-9. Nihon Rinsho. 1991. PMID: 1720470 Japanese. No abstract available.
• Chemotherapy of the acquired immune deficiency syndrome (AIDS): non-nucleoside inhibitors of the human immunodeficiency virus type 1 reverse transcriptase.

  De Clercq E. De Clercq E. Int J Immunopharmacol. 1991;13 Suppl 1:83-9. doi: 10.1016/0192-0561(91)90129-u. Int J Immunopharmacol. 1991. PMID: 1726686
• [HEPT and its related compounds as anti-HIV agents].

  Miyasaka T, Tanaka H, Baba M. Miyasaka T, et al. Nihon Rinsho. 1993 Sep;51 Suppl:200-6. Nihon Rinsho. 1993. PMID: 7505847 Review. Japanese. No abstract available.